骨髓单克隆浆细胞比例低于10%的新诊断多发性骨髓瘤36例临床特征与预后分析
回顾性分析北京协和医院36例骨髓浆细胞比例<10%的NDMM患者,与72例年龄性别匹配的≥10%患者对照。该亚群占全部NDMM的4.4%,ISS Ⅲ期比例更低、髓外病变更多、M蛋白和尿轻链更低,但一线治疗PFS和OS优于对照组。
要点
- 骨髓浆细胞<10%的NDMM占4.4%,ISS Ⅲ期比例显著低于对照组。
- 该亚群髓外病变比例更高,但血清M蛋白和24h尿轻链水平更低。
- 该亚群一线治疗PFS和OS均优于骨髓浆细胞≥10%患者。
核心结论
- 骨髓浆细胞比例<10%的NDMM患者疾病分期较早、肿瘤负荷较低,尽管髓外病变比例更高,一线疗效和总体预后优于比例≥10%的患者。
研究设计与样本
- 回顾性总结2009年1月至2017年12月北京协和医院36例骨髓浆细胞比例<10%的NDMM患者,选择同期72例年龄和性别匹配、骨髓浆细胞比例≥10%的NDMM患者作为对照。
主要发现
- 研究组占全部NDMM的4.4%(36/818),ISS Ⅲ期11例(30.6%),显著低于对照组45例(62.5%)(P=0.002)。
- 研究组髓外病变比例33.3%高于对照组5.6%(P<0.001),血清M蛋白中位值1.04(0~50.10)g/L低于对照组4.50(0~63.10)g/L(P=0.016)。
- 研究组24 h尿轻链定量中位值510 mg低于对照组2800 mg(P=0.023)。
- 研究组与对照组一线治疗后中位PFS分别为26.4个月和19.9个月(HR=1.703,95%CI 0.167~0.233,P=0.002),中位OS分别为65.8个月和46.2个月(HR=2.626,95%CI 0.439~0.541,P=0.058)。
- 研究组按M蛋白水平分层,低肿瘤负荷组与高肿瘤负荷组中位OS分别为66.4个月和24.0个月(HR=2.349,95%CI 0.603~0.696,P=0.046),中位PFS分别为33.1个月和15.5个月(HR=1.806,95%CI 0.121~0.399,P=0.077);硼替佐米治疗对生存结局无影响。
临床怎么用
- 对骨髓浆细胞比例<10%的NDMM患者应认识到其分期早、肿瘤负荷低但髓外病变比例高的特点,一线治疗预后较好。
- 该亚群中按M蛋白水平区分低/高肿瘤负荷可能有助于预后分层。
局限性
- 本研究为单中心回顾性分析,样本量较小(研究组36例),结论需更大规模研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To improve the understanding of newly diagnosed multiple myeloma (NDMM) patients with bone marrow (BM) monoclonal plasma cell ratio of less than 10%. Methods: The clinical characteristics, laboratory examination, response to treatment, and prognosis of 36 NDMM patients with BM plasma cell ratio of less than 10% at Peking Union Medical College Hospital from January 2009 to December 2017 were summarized retrospectively. In the same period, other age- and gender-matched 72 NDMM patients were selected as the control group, whose BM plasma cell ratio was equal to or greater than 10%. Results: First, the patients in the study group accounted for 4.4% of the whole MM population (36/818) , among which only 11 (30.6%) were classified as International Staging System (ISS) Ⅲ, which was significantly lower than that in the control group[45 (62.5%) ] (P=0.002) . Extramedullary disease (EMD) was more common in the study group (33.3%vs 5.6%, P<0.001) . The median quantity of serum M protein (g/L) in the less than 10% group was 1.04 (0-50.10) , which was significantly lower than that in the control group [4.50 (0-63.10) ] (P=0.016) , similar to the median quantity of 24-h urinary light chain (510 mg vs 2800 mg, respectively, P=0.023) . Second, the median progression-free survival (PFS) times of front-line regimen in the study and control groups were 26.4 and 19.9 months, respectively (HR=1.703, 95%CI 0.167-0.233, P=0.002) . In addition, the overall survival (OS) times were 65.8 and 46.2 months, respectively (HR=2.626, 95%CI 0.439-0.541, P=0.058) . Third, the study group was reclassified based on the quantity of M protein. The median OS times in patients with low/high tumor load were 66.4 and 24.0 months, respectively (HR=2.349, 95%CI 0.603-0.696, P=0.046) . The median PFS times were 33.1 and 15.5 months, respectively (HR=1.806, 95%CI 0.121-0.399, P=0.077) . Bortezomib-based regimens did not affect the clinical outcomes. Conclusion: The subpopulation of patients with MM with BM monoclonal plasma cell ratio less than 10% has specific clinical characteristics, including an early disease stage and a lower overall tumor load. Although more patients of this minor group presented with an extramedullary disease, their response rate to the initial treatment and survival outcome are better than those of patients with BM monoclonal plasma cell ratio more than 10%. 目的: 提高对骨髓单克隆浆细胞比例小于10%的新诊断多发性骨髓瘤(NDMM)患者的认识。 方法: 回顾性总结2009年1月至2017年12月北京协和医院36例骨髓浆细胞比例小于10%的NDMM患者的临床特点、实验室检查、治疗反应和预后情况,选择同期诊断的72例骨髓浆细胞比例≥10%的NDMM患者作为对照组,两组患者年龄和性别匹配。 结果: ①在818例NDMM患者中,骨髓浆细胞比例小于10%的患者36例(4.4%),其中国际分期系统(ISS)Ⅲ期11例(30.6%),显著低于对照组患者[45例(62.5%)](P=0.002)。与对照组相比,骨髓浆细胞比例小于10%的患者合并髓外病变比例更高(33.3%对5.6%,P<0.001),血清M蛋白中位值更低[1.04(0~50.10)g/L对4.50(0~63.10)g/L,P=0.016],24 h尿轻链定量中位值更低(510 mg对2800 mg,P=0.023)。②骨髓浆细胞比例小于10%患者与对照组患者一线治疗后中位无进展生存(PFS)时间分别为26.4个月和19.9个月(HR=1.703,95%CI 0.167~0.233,P=0.002),总生存(OS)时间分别为65.8个月和46.2个月(HR=2.626,95%CI 0.439~0.541,P=0.058)。③按照M蛋白水平将研究组分为低肿瘤负荷组和高肿瘤负荷组,中位OS时间分别为66.4个月和24.0个月(HR=2.349,95%CI 0.603~0.696,P=0.046),中位PFS时间分别为33.1个月和15.5个月(HR=1.806,95%CI 0.121~0.399,P=0.077)。硼替佐米治疗对患者的生存结局无影响。 结论: 骨髓浆细胞比例小于10%的NDMM患者疾病分期较早,肿瘤负荷较低,尽管合并髓外病变比例更高,一线疗效以及总体预后优于骨髓浆细胞比例≥10%的患者。.
引用
- Zhao JT, Jiang XY, Yang C, et al. [Analysis of the clinical characteristics and prognosis of 36 cases of newly diagnosed multiple myeloma patients with bone marrow monoclonal plasma cell ratio of less than 10]. Zhonghua Xue Ye Xue Za Zhi. 2021. PMID: 33979973. doi:10.3760/cma.j.issn.0253-2727.2021.04.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。